Hormone replacement therapy after myocardial infarction: British Menopause Society Tool for Clinicians

Stevenson JC . HRT for the primary prevention of coronary heart disease. In: Brinton R Genazzani A Simoncini T , et al. (eds) Sex steroids’ effects on brain, heart and vessels. ISGE series. Cham: Springer, 2019, pp. 257–264.

Stevenson JC . Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 2000; 74: 387–393.

Wingrove CS Garr E Godsland IF , et al. 17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998; 1406: 169–174.

Hodis HN Mack WJ Lobo RA , et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939–953.

Hodis HN Mack WJ Henderson VW , et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016; 374: 1221–1231.

Adams MR Register TC Golden DL , et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217–221.

Adams MR Kaplan JR Manuck SB , et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arterioscler Thromb Vasc Biol 1990; 10: 1051–1057.

Grodstein F Manson JE Colditz GA , et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.

Salpeter SR Walsh JME Greyber E , et al. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006; 21: 363–366.

Boardman HMP Hartley L Eisinga A , et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev 2015; 4: CD002229.

Cherry N Gilmour K Hannaford P ESPRIT team , et al. Estrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001–2008.

Cherry N McNamee R Heagerty A , et al. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised trial. BJOG 2014; 121: 700–705.

Hulley S Grady D Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.

Rosano GMC Simon T Mercuro T , et al. Hormone replacement therapy: where we stand in Europe. Eur Heart J 2001; 22: 439–441.

Herrington DM Vittinghoff E Lin F , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962–2967.

Collins P Flather M Lees B , et al. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 2006; 27: 2046–2053.

Grodstein F Manson JE Stampfer MJ . Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. Ann Intern Med 2001; 135: 1–8.

Schlipak MG Angeja BG Go AS , et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001; 104: 2300–2309.

Vinogradova Y Coupland C Hippisley-Cox J . Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364: k4810.

Scarabin P-Y Oger E Plu-Bureau G . Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432.